Boston, MA, 08/01/2013 (nysepost) – Recently, the stock of Inovio Pharmaceuticals Inc (NYSEMKT:INO) has found to shot up a larger 28.97% with the total number of 15.1 million shares being traded. On a technical view, the stock of Inovio Pharmaceuticals Inc has shot past the price of $ 1.50 stubborn level prior to 11.00 a.m. trading. However, the stock was found to take off during post 12.00 p.m. trading. Therefore, the stock has broken out of the increasing trend in triangle pattern. This led to the measuring implication which is the projected price of approximately $ 2.37. In this week’s trading, the shares of Inovio Pharmaceuticals Inc have also hit a new 12-month high. During the previous trading session, the stock of Inovio Pharmaceuticals Inc has earned a profit 0.69% at the price of $ 1.45 with the total numbers of 4.1 million shares being traded.
The stock of Inovio Pharmaceuticals Inc has been basking with the glow of positive results with regards to the human telomerase reverse transcriptase DNA vaccine for cancer which were administered into two of the animal models by making use of the CELLECTRA. The CELLECTRA is the adaptive technology of electroporation delivery of the vaccines. It has been announced by Inovio Pharmaceuticals Inc that the company’s hTERT DNA cancer vaccine has shown the potential for reducing the tumors and also for preventing the recurrence of tumors.
Per the reports by media, the focus of Inovio Pharmaceuticals Inc on oncology is holding the chances for making it an appropriate candidate for getting acquired by Merck. This is because Merck is suffering decline in the revenue from its oncology businesses. This has possibly helped the launch of of Inovio Pharmaceuticals Inc into one of the bullish trajectories. Inovio Pharmaceuticals Inc is a company that is re-owned for revolutionizing the vaccines that are intended for the prevention and treatment of cancers and some of the infectious diseases.
